• Eckert & Ziegler's therapeutics subsidiary received German manufacturing authorization for actinium-225, confirming compliance with Good Manufacturing Practice standards.
• The certification facilitates use of the radioisotope in investigational patient treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2416898_en) on October 28, 2026, and is solely responsible for the information contained therein.